BDBM802071 US20260108613, Compound A16::ethyl (R)-8-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4- methylthiazol-5-yl)phenyl)- ethyl)carbamoyl)pyrrolidine- 1-carbonyl)-7,7-dimethyl- 5,6,7,8-tetrahydro-4H-cyclo- hepta[d]isoxazole-3-carbox- ylate

SMILES CCOC(=O)c1noc2c1CCCC(C)(C)[C@H]2C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(-c2scnc2C)cc1

InChI Key InChIKey=ZPXBIURITMFGMG-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 802071   

Targetvon Hippel-Lindau disease tumor suppressor(Human)
University of Michigan

US Patent
LigandChemical structure of BindingDB Monomer ID 802071BDBM802071(ethyl (R)-8-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4- m...)
Affinity DataIC50: 8.60nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/2/2026
Entry Details
US Patent